Delivery Order SPE2DB22D2006-SPE2DB24FW0FH
- Not listed
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The order is for the supply of 4563752529 IPOL VIAL 5ML, a pharmaceutical product, with a potential value of $10,673.50 and a completion date of February 26, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order and has also been awarded an indefinite delivery contract (IDC) by DLA with a potential...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $12,645.16, is for the delivery of IPOL VIAL 5ML pharmaceutical products. It is a firm fixed-price contract with a period of performance through May 1, 2025. The contract is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support...
- This federal contract award was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The $1,163.64 firm fixed-price delivery order is for the supply of IPOL VIAL 5ML pharmaceutical products. Amerisourcebergen, a major pharmaceutical distribution company, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,682.98, is for the delivery of IPOL VIAL 5ML medical supplies. The contract is a firm fixed-price delivery order, with a performance period ending on May 1, 2025. It is not designated as a set-aside contract, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor,...
- The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract valued at $8,541.00 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of IPOL VIAL 5ML medical products, with a completion date of December 14, 2021. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,668.52 firm fixed-price delivery order is for the supply of 4567951715 IPOL VIAL 5ML, with a performance period ending on April 18, 2025. The contract is not set aside and is considered an open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the...
- This federal contract award is a delivery order with a firm fixed-price pricing type, valued at $54,405.01, awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the procurement of 4566173175 IPOL VIAL 5ML medical products, with an ultimate completion date of October 23, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of IPOL VIAL 5ML products. The contract has a ceiling value of $16,437.19 and a completion date of August 21, 2024. It is a firm fixed-price contract and does not have a set-aside designation. Amerisourcebergen, through its Corporate Office division, is the prime contractor for this award. The company has a broad range of federal...
- This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract, which has a potential value of $2,134.70, is for the delivery of IPOL VIAL 5ML pharmaceutical products to support military treatment programs and facilities. The contract does not have a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,486.05 firm fixed-price delivery order is for IPOL VIAL 5ML medical products. The award does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB24FW0FHDelivery Order
This is a delivery order under a larger Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The $42,694.00 firm fixed-price order is for the supply of 4564557634 IPOL VIAL 5ML, a pharmaceutical product, with a period of performance ending on May 10, 2024. Amerisourcebergen holds a single-award IDC with DLA Troop Support Medical valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver a wide range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The company also holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024. This particular delivery order does not have a set-aside designation, indicating it was awarded on a full and open competition basis. Amerisourcebergen Drug Corp is a subsidiary of the larger Amerisourcebergen Corporation, one of the largest pharmaceutical distribution companies globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $42.7k | 5/9/24 |